Key result
DurAVR THV demonstrates ~3% moderate or greater PPM in patients with small aortic annuli.
Why the study?
TAVI in patients with small aortic annuli is associated with an increased risk of prosthesis-patient mismatch.
Does the DurAVR THV provide acceptable 30-day clinical and echocardiographic outcomes in patients with small aortic annuli?
Observational
Does the DurAVR THV provide acceptable 30-day clinical and echocardiographic outcomes in patients with small aortic annuli?
The novel DurAVR THV demonstrates promising early echocardiographic and clinical outcomes, with low rates of prosthesis-patient mismatch and paravalvular leak in patients with small aortic annuli.
Hypothesis-generating for DurAVR in small annuli; randomized trials needed to confirm benefit versus approved valves.
BACKGROUND: Transcatheter aortic valve implantation (TAVI) in patients with small aortic annuli (SAA) is associated with an increased risk of prosthesis-patient mismatch (PPM). AIMS: This study assesses the 30-day performance of the novel balloon-expandable DurAVR transcatheter heart valve (THV), which features a unique single-piece biomimetic leaflet design, in patients with SAA. METHODS: , with a mean diameter of 22.7±1.0 mm. Outcomes at 30 days, including PPM, were evaluated per Valve Academic Research Consortium 3 criteria, with independent adjudication of clinical events and core laboratory analysis of post-implant transthoracic echocardiograms. RESULTS: , and a Doppler velocity index of 0.60±0.10. The incidence of moderate or greater PPM was 3%, and no patients experienced more than mild paravalvular leak. The rate of new permanent pacemaker implantation was 6%. CONCLUSIONS: In patients with SAA, the DurAVR THV demonstrated promising clinical and echocardiographic outcomes at 30 days. Longer-term follow-up in larger cohorts is needed to confirm these encouraging early results.
No takes yet. Share an insight, caveat, or question.
Backer et al. (2026) conducted an observational in Small aortic annuli. DurAVR transcatheter heart valve was evaluated on 30-day performance including prosthesis-patient mismatch (PPM). The DurAVR transcatheter heart valve demonstrated promising 30-day outcomes in patients with small aortic annuli, with a 3% incidence of moderate or greater prosthesis-patient mismatch.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: